Pharmaceutical companies operate on business models that emphasize continuous revenue streams, particularly through the treatment of chronic conditions like diabetes, hypertension, and high cholesterol. This approach contrasts sharply with the one-time profit from a cure. While treatments for diseases such as HIV and cancer generate ongoing revenue, the development and prioritization of cures face numerous economic and regulatory hurdles. Critics argue that Big Pharma’s focus on profit leads to the suppression of potential cures, and regulatory bodies and market control entities, like LegitScript, often act to maintain this status quo. This article examines the inherent economic incentives in the pharmaceutical industry that prioritize treatments over cures, the suppression of natural remedies, and the broader implications for global health.